U.S. Markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.17-0.00 (-1.16%)
At close: 3:58PM EDT
People also watch
IMUCGALECLDXIDRATHLD
Full screen
Previous Close0.17
Open0.17
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.17 - 0.17
52 Week Range0.14 - 0.98
Volume2,061,828
Avg. Volume2,108,346
Market Cap51.68M
Beta1.12
PE Ratio (TTM)-0.30
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube20 days ago

    ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cubelast month

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube4 months ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)